Previous Page
18
nanotimes
Companies Facts
discharge capabilities,” said Dr. Rick Rocheleau, UH- HNEI Director. “These characteristics are expected to help meet the integration challenges of high-penetra- tion solar energy sources.”
Altairnano had closed on a Share Subscription Ag- reement with Canon Investment Holdings Limited (Canon), through its affiliate, Energy Storage Techno- logy (China) Group Limited (EST). Under the terms of the agreement, Altairnano issued 37,036,807 com- mon shares to EST at $1.5528 per share, providing $57.5 million in proceeds to Altairnano. Following the closing of this transaction, there are 69,452,487 Altairnano common shares outstanding.
June 30, 2011. Financial highlights for the second quarter include:
A
• 18% growth in Development/Small Scale Manufac- turing contract revenue over second quarter 2010;
• 21% growth in Large Scale Manufacturing contract revenue over second quarter 2010;
• Received $3 million milestone payment resulting from AMRI’s collaboration with Bristol-Myers Squibb (BMS) for the initiation of a phase II study.
Total revenue for the second quarter of 2011 was $53.9 million, an increase of 9% compared to total revenue of $49.5 million reported in the second quarter of 2010. Total contract revenue for the se- cond quarter of 2011 was $43.5 million, an increase of 7% compared to total contract revenue of $40.7
MRI (NASDAQ: AMRI) reported financial and operating results for the second quarter ended
million reported in the second quarter of 2010. Total contract revenue encompasses revenue from AMRI’s Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing busi- ness components.
Total revenue for the six-month period ended June 30, 2011 was $110.8 million, an increase of $12.0 million or 12% compared to $98.8 million for the same period in 2010. Total contract revenue for the first six months of 2011 was $86.4 million, an incre- ase of $6.8 million or 9% from $79.6 million for the same period in 2010.
Moreover, Takeshi Yura, Ph.D., has been promoted to senior director of drug discovery services at its Singapore subsidiary.
in the current development of a novel spin process for making high performance fibers from AMSilk’s spider silk proteins. AMSilk is the first company able to deliver sufficient spider silk material for applica- tions development. AMSilk’s spider silk is inspired by the natural silk from spiders and produced through biotechnology with an industrial production plat- form.
PI Technologies Corp. (NASDAQ: ATNY; API), announced the availability of its newest techno-
MSilk and the Fraunhofer Institute for Applied Polymer Research (IAP), Germany, join forces
11-08 :: August 2011